Generic placeholder image

Current Drug Safety


ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure

Author(s): Sohail Qayyum, Huijun Dong, Dianne Kovacic, Sidra Sohail, Bradford Waters, Camille Thornton and Cathy E. Corbett

Volume 7, Issue 5, 2012

Page: [391 - 393] Pages: 3

DOI: 10.2174/1574886311207050013

Price: $65


A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.

Keywords: Drug induced hepatic failure, AIDS combination therapy, antiretroviral, NNRTI, Emtricitabine, hepatic failure, hepatotoxicity, gonococcal, syphilis, genital herpes

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy